Bookmark

Add to MyYahoo RSS

Amgen News

News on Amgen (Ticker: AMGN) continually updated from thousands of sources around the net.

6 hrs ago | MarketNewsVideo

Daily Dividend Report: K, WWE, AMGN, ETR, AVY, RBC

Kellogg declared a dividend of $0.49 per share on the common stock of the Company.

Comment?

Related Topix: Kellogg, Food, Agriculture, Biotech, Medicine, Amgen, Healthcare Industry, Business News, Video

Fri Jul 25, 2014

Medical News

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary , today announced that an investigational Phase 3 trial of NEXAVAR tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival .

Comment?

Related Topix: Manufacturing, Bayer HealthCare, Chemicals, Biotech, Startups, Onyx Pharmaceuticals, Medicine, Amgen, Healthcare Industry, Xeloda, Capecitabine (generic), Health

Thu Jul 24, 2014

Freshnews

Amgen Announces Webcast of 2014 Second Quarter Financial Results

Amgen today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets.

Comment?

Related Topix: Biotech, Amgen, Healthcare Industry

Wed Jul 23, 2014

Seeking Alpha

IPO Preview: Atara Biotherapeutics

Clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology.

Comment?

Related Topix: Oncology, Medicine, San Mateo County, CA, Brisbane, CA

Tue Jul 22, 2014

The Motley Fool

Why Investors Continue to Flee Aegerion Stock

Although it's easy to generate huge commercial expectations for rare disease drugs , many companies report very underwhelming sales figures once the drug is brought to market.

Comment?

Related Topix: Healthcare Law, Law, Marketing

Seeking Alpha

Amgen Can Propel Over $120 With Earnings Right Around The Corner

The company posts successful results for the Phase 3 safety and efficacy testing of AMG 416, their secondary hyperthyroidism product.

Comment?

Related Topix: Biotech, Amgen, Medicine, Healthcare Industry

Mon Jul 21, 2014

The Motley Fool

Yellen Hates Biotech Stocks! Should You?

Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued.

Comment?

Related Topix: Biotech, Science / Technology, Financial Markets, Medicine, Healthcare Industry, Gilead Sciences

Freshnews

Colorado BioScience Association Recognizes Amgen Foundation's...

The Colorado BioScience Association is honored to recognize the Amgen Foundation's grant of $25,000 to the Colorado BioScience Institute in support of the Research Experience for Teachers program, in addition to funds provided by others including The Anschutz Foundation.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Non-Profit

Seeking Alpha

Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?

Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed.

Comment?

Related Topix: Biotech, Biogen Idec, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, Financial Markets

Sat Jul 19, 2014

The Motley Fool

This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results

With the SPDR S&P Biotech Index up 18% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.

Comment?

Related Topix: Food and Drug Administration, Marketing

Fri Jul 18, 2014

Seeking Alpha

Amgen: Grappling With The Reality Of Patent Expiries

The prevalence rate is quite high, with limited treatment options available. If authorized, Amgen can exploit the first-mover advantage.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Leukemia, Health, Neupogen, Filgrastim (generic)

Thu Jul 17, 2014

BioSpace

Amgen Thyroid Drug AMG 416 Succeeds In Late Stage Kidney Patient Trial

Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis Analysis Shows Study Met Primary and All Secondary EndpointsAMG 416 is a Novel Calcimimetic Administered Intravenously /PRNewswire/ -- Amgen today announced that a Phase 3 study ... (more)

Comment?

Related Topix: Biotech, Amgen, Medicine, Healthcare Industry

Freshnews

Amgen Announces Positive Phase 3 Results for AMG 416 for the...

Amgen today announced that a Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease , receiving hemodialysis, met its primary and all secondary endpoints.

Comment?

Related Topix: Biotech, Amgen, Medicine, Healthcare Industry

Wed Jul 16, 2014

BioSpace

That Model Genentech, Gilead Sciences, Inc., And Amgen Were Built On - Does It Work Anymore?

"The model is broken." I used to hear that chant from biotech VCs all the time, often accompanied by the thwack of self-flagellation.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Amgen, Healthcare Industry, Startups

Tue Jul 08, 2014

TechCrunch

Experimenting With Drugs In The Cloud

A science lab in Mountain View, CA is creating faster and cheaper drug experiments by putting them in the cloud.

Comment?

Related Topix: Science / Technology, Robots, Healthcare Law, Law, Food and Drug Administration

Thu Jul 03, 2014

Benzinga

Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

Large-cap biotech stocks should see healthy second-quarter results driven by strong demand and new products, a Citi analyst said Thursday.

Comment?

Related Topix: Financial Markets, Alexion Pharmaceuticals, Biotech, Taligen Therapeutics, Medicine, Healthcare Industry, Amgen, Enbrel, Etanercept (generic)

The Motley Fool

Biotech Stocks to Watch Today: AbbVie, Bind Therapeutics, MannKind, and Shire

Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie ( AbbVie still pursuing Shire Despite three rejections so far, AbbVie is reportedly still attempting to convince Shire and its major shareholders that a buyout is in their best interest.

Comment?

Related Topix: Movetis

Wed Jul 02, 2014

San Fernando Business Journal

Amgen Leukemia Drug Receives Fast-Track Status

The U.S. Food and Drug Administration has given Breakthrough Therapy Designation status to blinatumomab, a drug in development at Amgen Inc. for treating certain cancers.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Leukemia, Health, Food and Drug Administration

Tue Jul 01, 2014

BioSpace

Amgen Wins FDA Breakthrough Therapy Designation For Investigational BiTE

The Breakthrough Therapy Designation was based on the results of a Phase 2 trial of 189 adult patients with Ph- relapsed/refractory B-precursor ALL treated with blinatumomab.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration

Freshnews

Amgen Receives FDA Breakthrough Therapy Designation For...

Amgen today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to investigational bispecific T cell engager ) antibody blinatumomab, for adults with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia , a rapidly progressing cancer of the blood and bone marrow .

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••